Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Retained Earnings (2016 - 2025)

Historic Retained Earnings for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$46.0 million.

  • China Pharma Holdings' Retained Earnings fell 747.1% to -$46.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$46.0 million, marking a year-over-year decrease of 747.1%. This contributed to the annual value of -$44.0 million for FY2024, which is 1205.48% down from last year.
  • China Pharma Holdings' Retained Earnings amounted to -$46.0 million in Q3 2025, which was down 747.1% from -$45.3 million recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Retained Earnings ranged from a high of -$29.6 million in Q1 2021 and a low of -$46.0 million during Q3 2025
  • Its 5-year average for Retained Earnings is -$37.8 million, with a median of -$37.3 million in 2023.
  • Its Retained Earnings has fluctuated over the past 5 years, first plummeted by 1431.63% in 2021, then crashed by 747.1% in 2025.
  • Over the past 5 years, China Pharma Holdings' Retained Earnings (Quarter) stood at -$32.2 million in 2021, then dropped by 12.32% to -$36.2 million in 2022, then dropped by 8.5% to -$39.3 million in 2023, then decreased by 12.05% to -$44.0 million in 2024, then decreased by 4.48% to -$46.0 million in 2025.
  • Its last three reported values are -$46.0 million in Q3 2025, -$45.3 million for Q2 2025, and -$44.8 million during Q1 2025.